Filing summary
Entity and period: The supplied filing is PainReform Ltd.’s annual report on Form 20-F for the fiscal year ended December 31, 2021, filed March 16, 2022. This does not match the request metadata name “PRF Technologies Ltd.” The report presents annual results, not a standalone fourth-quarter report. Financial statements are in U.S. dollars and prepared under U.S. GAAP.
Business context
PainReform is a clinical-stage specialty pharmaceutical company developing PRF-110, an extended-release ropivacaine formulation intended to treat post-surgical pain and reduce opioid use. The company had no approved products and had not generated revenue. It planned two Phase 3 trials—bunionectomy and hernia repair—using the FDA’s 505(b)(2) pathway.
Financial performance and position
| Metric (US$ millions, except per-share data) | FY 2021 | FY 2020 | Change or context |
|---|---|---|---|
| Revenue | None | None | No product revenue to date |
| Research and development expense | 2.860 | 0.354 | Up 715%, primarily Phase 3 preparation |
| General and administrative expense | 4.348 | 1.317 | Up 228%, including professional services, D&O insurance, clinical-trial-related costs and payroll |
| Operating loss | 7.208 | 1.671 | Reflects increased operating spend |
| Financial expense, net | 0.032 | 2.162 | Lower mainly because of reduced warrant revaluation and convertible-note costs |
| Net loss | 7.246 | 4.053 | Loss widened 79%; basic and diluted loss per share was $0.74 versus $1.25 |
| Net cash used in operating activities | 6.553 | 2.557 | Cash use increased with personnel, consulting, clinical-trial and insurance costs |
| Cash and cash equivalents at year-end | 16.537 | 15.677 | Restricted cash was an additional $0.034 million in 2021 |
| Total current assets | 19.020 | 17.791 | |
| Total current liabilities | 0.757 | 0.961 | |
| Total liabilities | 0.991 | 1.181 | No material interest-bearing debt is reported at year-end |
| Working capital | 18.3 | Not stated | Reported by management as positive |
Financing cash inflow was $7.484 million in 2021, including $5.554 million net proceeds from a March private placement and approximately $1.930 million from warrant exercises. Cash and restricted cash increased by $0.881 million. There were no material investing cash flows and no off-balance-sheet arrangements reported. The company reported an accumulated deficit of $23.727 million.
Material changes, outlook and risks
- Manufacturing delay: Problems at the former Israeli contract manufacturer, including facility regulatory failures, GMP issues and staff turnover, delayed clinical-trial batches. PainReform shifted manufacturing and scale-up to North America and engaged Pharmaceutics International; process validation remained underway.
- Clinical outlook: Management expected to begin the first, bunionectomy Phase 3 trial in the second half of 2022, after validation and production of trial batches. It planned the hernia-repair trial after successful completion of the first trial. These are forward-looking plans, not completed milestones.
- Funding: Management believed available resources would fund operating and capital needs for at least 12 months from the report’s issuance date. It also stated that additional funding would be required to complete development and pursue commercialization; no committed external funding source was identified.
- Commitments: Disclosed CRO-related contractual obligations totaled approximately $8.949 million, including $1.744 million due in less than one year and $7.205 million in one to three years. The commitments relate to clinical research and trial agreements and are subject to their terms.
- Key risks: Continued losses and financing dependence; reliance on PRF-110; clinical, regulatory and manufacturing uncertainty; dependence on third-party manufacturers and some single-source materials; competition and reimbursement uncertainty; COVID-19 and geopolitical disruption, including the Russia-Ukraine conflict; and risks associated with operations in Israel and intellectual-property protection.
- Other notable disclosures: PainReform said it had no material legal proceedings and did not intend to pay dividends. It believed it was not a PFIC for 2021 but said 2022 status was uncertain. Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2021; the auditor did not provide an internal-control attestation because of the emerging-growth-company exemption.
Investor verification points
- Confirm the issuer identity: the filing is for PainReform Ltd., not “PRF Technologies Ltd.”
- Check whether manufacturing validation was completed and whether the planned Phase 3 trial actually began on schedule.
- Review subsequent cash burn, financing, dilution and the company’s updated liquidity runway.
- Reconcile reported trial commitments with amounts paid, prepaid clinical-trial costs and any changes to CRO or CMO agreements.
- Track clinical results, regulatory feedback and whether PRF-110 demonstrates safety and efficacy sufficient for approval and market adoption.
- Consider the filing’s disclosed limitations on auditor attestation, foreign-private-issuer reporting and corporate-governance practices.